<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37628685</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Advancing Epidemiology and Genetic Approaches for the Treatment of Spinal and Bulbar Muscular Atrophy: Focus on Prevalence in the Indigenous Population of Western Canada.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes14081634</ELocationID><Abstract><AbstractText>Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is a debilitating neuromuscular disease characterized by progressive muscular weakness and neuronal degeneration, affecting 1-2 individuals per 100,000 globally. While SBMA is relatively rare, recent studies have shown a significantly higher prevalence of the disease among the indigenous population of Western Canada compared to the general population. The disease is caused by a pathogenic expansion of polyglutamine residues in the androgen receptor protein, which acts as a key transcriptional regulator for numerous genes. SBMA has no cure, and current treatments are primarily supportive and focused on symptom management. Recently, a form of precision medicine known as antisense therapy has gained traction as a promising therapeutic option for numerous neuromuscular diseases. Antisense therapy uses small synthetic oligonucleotides to confer therapeutic benefit by acting on pathogenic mRNA molecules, serving to either degrade pathogenic mRNA transcripts or helping to modulate splicing. Recent studies have explored the suitability of antisense therapy for the treatment of SBMA, primarily focused on gene therapy and antisense-mediated mRNA knockdown approaches. Advancements in understanding the pathogenesis of SBMA and the development of targeted therapies offer hope for improved quality of life for individuals affected by this debilitating condition. Continued research is essential to optimize these genetic approaches, ensuring their safety and efficacy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wilton-Clark</LastName><ForeName>Harry</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-2696-265X</Identifier><AffiliationInfo><Affiliation>Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Aghbari</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-9129-5929</Identifier><AffiliationInfo><Affiliation>Department of Biological Sciences, Faculty of Science, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Immunology, Department of Pharmacology and Toxicology, Faculty of Arts and Science, University of Toronto, Toronto, ON M5S 1A1, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yokota</LastName><ForeName>Toshifumi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-6672-6742</Identifier><AffiliationInfo><Affiliation>Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="Y">Bulbo-Spinal Atrophy, X-Linked</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081034" MajorTopicYN="N">Indigenous Peoples</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009133" MajorTopicYN="N">Muscular Atrophy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AR45</Keyword><Keyword MajorTopicYN="N">androgen receptor</Keyword><Keyword MajorTopicYN="N">antisense therapy</Keyword><Keyword MajorTopicYN="N">mRNA knockdown</Keyword><Keyword MajorTopicYN="N">oligonucleotide</Keyword><Keyword MajorTopicYN="N">spinal and bulbar muscular atrophy</Keyword><Keyword MajorTopicYN="N">splice switching</Keyword></KeywordList><CoiStatement>H.W.-C., A.A.-a. and J.Y. declare no conflicts of interest. T.Y. is a founder and shareholder of OligomicsTx, which aims to commercialize antisense oligonucleotide technology.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>28</Day><Hour>7</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37628685</ArticleId><ArticleId IdType="pmc">PMC10454234</ArticleId><ArticleId IdType="doi">10.3390/genes14081634</ArticleId><ArticleId IdType="pii">genes14081634</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kennedy W.R., Alter M., Sung J.H. Progressive Proximal Spinal and Bulbar Muscular Atrophy of Late Onset. Neurology. 1968;18:671. doi: 10.1212/WNL.18.7.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.18.7.671</ArticleId><ArticleId IdType="pubmed">4233749</ArticleId></ArticleIdList></Reference><Reference><Citation>Banno H., Katsuno M., Suzuki K., Tanaka F., Sobue G. Pathogenesis and Molecular Targeted Therapy of Spinal and Bulbar Muscular Atrophy (SBMA) Cell Tissue Res. 2012;349:313&#x2013;320. doi: 10.1007/s00441-012-1377-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-012-1377-9</ArticleId><ArticleId IdType="pubmed">22476656</ArticleId></ArticleIdList></Reference><Reference><Citation>Atsuta N., Watanabe H., Ito M., Banno H., Suzuki K., Katsuno M., Tanaka F., Tamakoshi A., Sobue G. Natural History of Spinal and Bulbar Muscular Atrophy (SBMA): A Study of 223 Japanese Patients. Brain. 2006;129:1446&#x2013;1455. doi: 10.1093/brain/awl096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl096</ArticleId><ArticleId IdType="pubmed">16621916</ArticleId></ArticleIdList></Reference><Reference><Citation>Malena A., Pennuto M., Tezze C., Querin G., D&#x2019;Ascenzo C., Silani V., Cenacchi G., Scaramozza A., Romito S., Morandi L., et al. Androgen-Dependent Impairment of Myogenesis in Spinal and Bulbar Muscular Atrophy. Acta Neuropathol. 2013;126:109&#x2013;121. doi: 10.1007/s00401-013-1122-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1122-9</ArticleId><ArticleId IdType="pubmed">23644820</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorar&#xf9; G., D&#x2019;Ascenzo C., Polo A., Palmieri A., Baggio L., Vergani L., Gellera C., Moretto G., Pegoraro E., Angelini C. Spinal and Bulbar Muscular Atrophy: Skeletal Muscle Pathology in Male Patients and Heterozygous Females. J. Neurol. Sci. 2008;264:100&#x2013;105. doi: 10.1016/j.jns.2007.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2007.08.012</ArticleId><ArticleId IdType="pubmed">17854832</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgetti E., Lieberman A.P. Polyglutamine Androgen Receptor-Mediated Neuromuscular Disease. Cell Mol. Life Sci. 2016;73:3991. doi: 10.1007/s00018-016-2275-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2275-1</ArticleId><ArticleId IdType="pmc">PMC5045769</ArticleId><ArticleId IdType="pubmed">27188284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman A.P., Yu Z., Murray S., Peralta R., Low A., Guo S., Yu X.X., Cortes C.J., Bennett C.F., Monia B.P., et al. Peripheral Androgen Receptor Gene Suppression Rescues Disease in Mouse Models of Spinal and Bulbar Muscular Atrophy. Cell Rep. 2014;7:774&#x2013;784. doi: 10.1016/j.celrep.2014.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.02.008</ArticleId><ArticleId IdType="pmc">PMC4356525</ArticleId><ArticleId IdType="pubmed">24746732</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejager S., Bry-Gauillard H., Bruckert E., Eymard B., Salachas F., LeGuern E., Tardieu S., Chadarevian R., Giral P., Turpin G. A Comprehensive Endocrine Description of Kennedy&#x2019;s Disease Revealing Androgen Insensitivity Linked to CAG Repeat Length. J. Clin. Endocrinol. Metab. 2002;87:3893&#x2013;3901. doi: 10.1210/JCEM.87.8.8780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/JCEM.87.8.8780</ArticleId><ArticleId IdType="pubmed">12161529</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbohm A., Hirsch S., Volk A.E., Grehl T., Grosskreutz J., Hanisch F., Herrmann A., Kollewe K., Kress W., Meyer T., et al. The Metabolic and Endocrine Characteristics in Spinal and Bulbar Muscular Atrophy. J. Neurol. 2018;265:1026&#x2013;1036. doi: 10.1007/s00415-018-8790-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-8790-2</ArticleId><ArticleId IdType="pubmed">29464380</ArticleId></ArticleIdList></Reference><Reference><Citation>Querin G., Bertolin C., Da Re E., Volpe M., Zara G., Pegoraro E., Caretta N., Foresta C., Silvano M., Corrado D., et al. Non-Neural Phenotype of Spinal and Bulbar Muscular Atrophy: Results from a Large Cohort of Italian Patients. J. Neurol. Neurosurg. Psychiatry. 2016;87:810&#x2013;816. doi: 10.1136/jnnp-2015-311305.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311305</ArticleId><ArticleId IdType="pmc">PMC4975824</ArticleId><ArticleId IdType="pubmed">26503015</ArticleId></ArticleIdList></Reference><Reference><Citation>Francini-Pesenti F., Querin G., Martini C., Mareso S., Sacerdoti D. Prevalence of Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease in a Cohort of Italian Patients with Spinal-Bulbar Muscular Atrophy. Acta Myol. 2018;37:204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6390113</ArticleId><ArticleId IdType="pubmed">30838350</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka F., Katsuno M., Banno H., Suzuki K., Adachi H., Sobue G. Current Status of Treatment of Spinal and Bulbar Muscular Atrophy. Neural Plast. 2012;2012:369284. doi: 10.1155/2012/369284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/369284</ArticleId><ArticleId IdType="pmc">PMC3376774</ArticleId><ArticleId IdType="pubmed">22720173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P.F., Bernard E., Corcia P., Couratier P., Jublanc C., Querin G., Mor&#xe9;lot Panzini C., Salachas F., Vial C., Wahbi K., et al. The French National Protocol for Kennedy&#x2019;s Disease (SBMA): Consensus Diagnostic and Management Recommendations. Orphanet J. Rare Dis. 2020;15:90. doi: 10.1186/s13023-020-01366-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-020-01366-z</ArticleId><ArticleId IdType="pmc">PMC7149864</ArticleId><ArticleId IdType="pubmed">32276665</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidetti D., Sabadini R., Ferlini A., Torrente I. Epidemiological Survey of X-Linked Bulbar and Spinal Muscular Atrophy, or Kennedy Disease, in the Province of Reggio Emilia, Italy. Eur. J. Epidemiol. 2001;17:587&#x2013;591. doi: 10.1023/A:1014580219761.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1014580219761</ArticleId><ArticleId IdType="pubmed">11949733</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund A., Udd B., Juvonen V., Andersen P.M., Cederquist K., Davis M., Gellera C., K&#xf6;lmel C., Ronnevi L.O., Sperfeld A.D., et al. Multiple Founder Effects in Spinal and Bulbar Muscular Atrophy (SBMA, Kennedy Disease) around the World. Eur. J. Hum. Genet. 2001;9:431&#x2013;436. doi: 10.1038/sj.ejhg.5200656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5200656</ArticleId><ArticleId IdType="pubmed">11436124</ArticleId></ArticleIdList></Reference><Reference><Citation>Leckie J.N., Joel M.M., Martens K., King A., King M., Korngut L.W., de Koning A.P.J., Pfeffer G., Schellenberg K.L. Highly Elevated Prevalence of Spinobulbar Muscular Atrophy in Indigenous Communities in Canada Due to a Founder Effect. Neurol. Genet. 2021;7:e607. doi: 10.1212/NXG.0000000000000607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000607</ArticleId><ArticleId IdType="pmc">PMC8267784</ArticleId><ArticleId IdType="pubmed">34250227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund A., Udd B., Juvonen V., Andersen P.M., Cederquist K., Ronnevi L.O., Sistonen P., S&#xf6;rensen S.A., Tranebj&#xe6;rg L., Wallgren-Pettersson C., et al. Founder Effect in Spinal and Bulbar Muscular Atrophy (SBMA) in Scandinavia. Eur. J. Hum. Genet. 2000;8:631&#x2013;636. doi: 10.1038/sj.ejhg.5200517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejhg.5200517</ArticleId><ArticleId IdType="pubmed">10951525</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka F., Doyu M., Ito Y., Matsumoto M., Mitsuma T., Abe K., Aoki M., Itoyama Y., Fischbeck K.H., Sobue G. Founder Effect in Spinal and Bulbar Muscular Atrophy (SBMA) Hum. Mol. Genet. 1996;5:1253&#x2013;1257. doi: 10.1093/hmg/5.9.1253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/5.9.1253</ArticleId><ArticleId IdType="pubmed">8872464</ArticleId></ArticleIdList></Reference><Reference><Citation>King M., Smith A., Gracey M. Indigenous Health Part 2: The Underlying Causes of the Health Gap. Lancet. 2009;374:76&#x2013;85. doi: 10.1016/S0140-6736(09)60827-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)60827-8</ArticleId><ArticleId IdType="pubmed">19577696</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin D., Miller A.P., Quesnel-Vall&#xe9;e A., Caron N.R., Vissandj&#xe9;e B., Marchildon G.P. Canada&#x2019;s Universal Health-Care System: Achieving Its Potential. Lancet. 2018;391:1718&#x2013;1735. doi: 10.1016/S0140-6736(18)30181-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)30181-8</ArticleId><ArticleId IdType="pmc">PMC7138369</ArticleId><ArticleId IdType="pubmed">29483027</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron N.R., Chongo M., Hudson M., Arbour L., Wasserman W.W., Robertson S., Correard S., Wilcox P. Indigenous Genomic Databases: Pragmatic Considerations and Cultural Contexts. Front. Public Health. 2020;8:529095. doi: 10.3389/fpubh.2020.00111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00111</ArticleId><ArticleId IdType="pmc">PMC7193324</ArticleId><ArticleId IdType="pubmed">32391301</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong E.L., Loy C.J., Sim K.S. Androgen Receptor Gene and Male Infertility. Hum. Reprod. Update. 2003;9:1&#x2013;7. doi: 10.1093/humupd/dmg003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humupd/dmg003</ArticleId><ArticleId IdType="pubmed">12638777</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu N.Z., Wardell S.E., Burnstein K.L., Defranco D., Fuller P.J., Giguere V., Hochberg R.B., Mckay L., Renoir J.M., Weigel N.L., et al. International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors. Pharmacol. Rev. 2006;58:782&#x2013;797. doi: 10.1124/pr.58.4.9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.58.4.9</ArticleId><ArticleId IdType="pubmed">17132855</ArticleId></ArticleIdList></Reference><Reference><Citation>Palazzolo I., Gliozzi A., Rusmini P., Sau D., Crippa V., Simonini F., Onesto E., Bolzoni E., Poletti A. The Role of the Polyglutamine Tract in Androgen Receptor. J. Steroid Biochem. Mol. Biol. 2008;108:245&#x2013;253. doi: 10.1016/j.jsbmb.2007.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jsbmb.2007.09.016</ArticleId><ArticleId IdType="pubmed">17945479</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown C.J., Goss S.J., Lubahn D.B., Joseph D.R., Wilson E.M., French F.S., Willard H.F. Androgen Receptor Locus on the Human X Chromosome: Regional Localization to Xq11-12 and Description of a DNA Polymorphism. Am. J. Hum. Genet. 1989;44:264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1715398</ArticleId><ArticleId IdType="pubmed">2563196</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubahn D.B., Joseph D.R., Sullivan P.M., Willard H.F., French F.S., Wilson E.M. Cloning of Human Androgen Receptor Complementary DNA and Localization to the X Chromosome. Science. 1988;240:327&#x2013;330. doi: 10.1126/science.3353727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3353727</ArticleId><ArticleId IdType="pubmed">3353727</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C., Kokontis J., Liao S. Molecular Cloning of Human and Rat Complementary DNA Encoding Androgen Receptors. Science. 1988;240:324&#x2013;326. doi: 10.1126/science.3353726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.3353726</ArticleId><ArticleId IdType="pubmed">3353726</ArticleId></ArticleIdList></Reference><Reference><Citation>van Laar J.H., de Vries J.B., Voorhorst-Ogink M.M., Brinkmann A.O. The Human Androgen Receptor Is a 110 KDa Protein. Mol. Cell Endocrinol. 1989;63:39&#x2013;44. doi: 10.1016/0303-7207(89)90079-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0303-7207(89)90079-8</ArticleId><ArticleId IdType="pubmed">2787763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiper G.G.J.M., Faber P.W., Van Rooij H.C.J., Van der Korput J.A.G.M., Ris-Stalpers C., Klaassen P., Trapman J., Brinkmann A.O. Structural organization of the human androgen receptor gene. J. Mol. Endocrinol. 1989;2:R1&#x2013;R4. doi: 10.1677/jme.0.002R001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/jme.0.002R001</ArticleId><ArticleId IdType="pubmed">2546571</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.J., O&#x2019;Malley B.W. Molecular Mechanisms of Action of Steroid/Thyroid Receptor Superfamily Members. Annu. Rev. Biochem. 1994;63:451&#x2013;486. doi: 10.1146/annurev.bi.63.070194.002315.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.63.070194.002315</ArticleId><ArticleId IdType="pubmed">7979245</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmann A.O. Molecular Basis of Androgen Insensitivity. Mol. Cell Endocrinol. 2001;179:105&#x2013;109. doi: 10.1016/S0303-7207(01)00466-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0303-7207(01)00466-X</ArticleId><ArticleId IdType="pubmed">11420135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischbeck K.H., Lieberman A., Bailey C.K., Abel A., Merry D.E. Androgen Receptor Mutation in Kennedy&#x2019;s Disease. Philos. Trans. R. Soc. B: Biol. Sci. 1999;354:1075. doi: 10.1098/rstb.1999.0461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.1999.0461</ArticleId><ArticleId IdType="pmc">PMC1692603</ArticleId><ArticleId IdType="pubmed">10434308</ArticleId></ArticleIdList></Reference><Reference><Citation>Fratta P., Collins T., Pemble S., Nethisinghe S., Devoy A., Giunti P., Sweeney M.G., Hanna M.G., Fisher E.M.C. Sequencing Analysis of the Spinal Bulbar Muscular Atrophy CAG Expansion Reveals Absence of Repeat Interruptions. Neurobiol. Aging. 2014;35:443.e1. doi: 10.1016/j.neurobiolaging.2013.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.07.015</ArticleId><ArticleId IdType="pmc">PMC3898077</ArticleId><ArticleId IdType="pubmed">24041967</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoyas C.A., La Spada A.R. The CAG&#x2013;Polyglutamine Repeat Diseases: A Clinical, Molecular, Genetic, and Pathophysiologic Nosology. Handb. Clin. Neurol. 2018;147:143&#x2013;170. doi: 10.1016/B978-0-444-63233-3.00011-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-444-63233-3.00011-7</ArticleId><ArticleId IdType="pubmed">29325609</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelmann E.P. Molecular Biology of the Androgen Receptor. J. Clin. Oncol. 2002;20:3001&#x2013;3015. doi: 10.1200/JCO.2002.10.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2002.10.018</ArticleId><ArticleId IdType="pubmed">12089231</ArticleId></ArticleIdList></Reference><Reference><Citation>Ing N.H., Beekman J.M., Tsai S.Y., Tsai M.-J., O&#x2019;malleyl B.W., Sagami I., Tsai S.Y., Wang H., Tsii M.-J., Malley O., et al. Members of the Steroid Hormone Receptor Superfamily Interact with TFIIB (S300-11) J. Biol. Chem. 1992;267:17617&#x2013;17623. doi: 10.1016/S0021-9258(19)37087-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)37087-5</ArticleId><ArticleId IdType="pubmed">1517211</ArticleId></ArticleIdList></Reference><Reference><Citation>Baniahmad A., Ha I., Reinberg D., Tsai S., Tsai M.J., O&#x2019;Malley B.W. Interaction of Human Thyroid Hormone Receptor Beta with Transcription Factor TFIIB May Mediate Target Gene Derepression and Activation by Thyroid Hormone. Proc. Natl. Acad. Sci. USA. 1993;90:8832&#x2013;8836. doi: 10.1073/pnas.90.19.8832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.90.19.8832</ArticleId><ArticleId IdType="pmc">PMC47454</ArticleId><ArticleId IdType="pubmed">8415616</ArticleId></ArticleIdList></Reference><Reference><Citation>Brou C., Chaudhary S., Davidson I., Lutz Y., Wu J., Egly J.M., Tora L., Chambon P. Distinct TFIID Complexes Mediate the Effect of Different Transcriptional Activators. EMBO J. 1993;12:489&#x2013;499. doi: 10.1002/j.1460-2075.1993.tb05681.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1460-2075.1993.tb05681.x</ArticleId><ArticleId IdType="pmc">PMC413232</ArticleId><ArticleId IdType="pubmed">8440239</ArticleId></ArticleIdList></Reference><Reference><Citation>Brou C., Wu J., Ali S., Scheer E., Lang C., Davidson I., Chambon P., Tora L. Different TBP-Associated Factors Are Required for Mediating the Stimulation of Transcription in Vitro by the Acidic Transactivator GAL-VP16 and the Two Nonacidic Activation Functions of the Estrogen Receptor. Nucleic Acids Res. 1993;21:5. doi: 10.1093/nar/21.1.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/21.1.5</ArticleId><ArticleId IdType="pmc">PMC309058</ArticleId><ArticleId IdType="pubmed">8441620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcewan I.J., Gustafsson J.&#xc5;. Interaction of the Human Androgen Receptor Transactivation Function with the General Transcription Factor&#x2009;TFIIF. Proc. Natl. Acad. Sci. USA. 1997;94:8485. doi: 10.1073/pnas.94.16.8485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.16.8485</ArticleId><ArticleId IdType="pmc">PMC22967</ArticleId><ArticleId IdType="pubmed">9238003</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulman I.G., Chakravarti D., Juguilon H., Romo A., Evans R.M. Interactions between the Retinoid X Receptor and a Conserved Region of the TATA-Binding Protein Mediate Hormone-Dependent Transactivation. Proc. Natl. Acad. Sci. USA. 1995;92:8288. doi: 10.1073/pnas.92.18.8288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.92.18.8288</ArticleId><ArticleId IdType="pmc">PMC41142</ArticleId><ArticleId IdType="pubmed">7667283</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas P.S., Fraley G.S., Damien V., Woodke L.B., Zapata F., Sopher B.L., Plymate S.R., La Spada A.R. Loss of Endogenous Androgen Receptor Protein Accelerates Motor Neuron Degeneration and Accentuates Androgen Insensitivity in a Mouse Model of X-Linked Spinal and Bulbar Muscular Atrophy. Hum. Mol. Genet. 2006;15:2225&#x2013;2238. doi: 10.1093/hmg/ddl148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddl148</ArticleId><ArticleId IdType="pubmed">16772330</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoghbi H.Y., Orr H.T. Glutamine Repeats and Neurodegeneration. Annu. Rev. Neurosci. 2000;23:217&#x2013;247. doi: 10.1146/annurev.neuro.23.1.217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.23.1.217</ArticleId><ArticleId IdType="pubmed">10845064</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross C.A. When More Is Less: Pathogenesis of Glutamine Repeat Neurodegenerative Diseases. Neuron. 1995;15:493&#x2013;496. doi: 10.1016/0896-6273(95)90138-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(95)90138-8</ArticleId><ArticleId IdType="pubmed">7546729</ArticleId></ArticleIdList></Reference><Reference><Citation>Craig T.J., Henley J.M. Fighting Polyglutamine Disease by Wrestling with SUMO. J. Clin. Investig. 2015;125:498&#x2013;500. doi: 10.1172/JCI80278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI80278</ArticleId><ArticleId IdType="pmc">PMC4319405</ArticleId><ArticleId IdType="pubmed">25607836</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Nakagomi Y., Kobayashi Y., Merry D.E., Tanaka F., Doyu M., Mitsuma T., Hashizume Y., Fischbeck K.H., Sobue G. Nonneural Nuclear Inclusions of Androgen Receptor Protein in Spinal and Bulbar Muscular Atrophy. Am. J. Pathol. 1998;153:695&#x2013;701. doi: 10.1016/S0002-9440(10)65612-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)65612-X</ArticleId><ArticleId IdType="pmc">PMC1853004</ArticleId><ArticleId IdType="pubmed">9736019</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold F.J., Merry D.E. Molecular Mechanisms and Therapeutics for SBMA/Kennedy&#x2019;s Disease. Neurotherapeutics. 2019;16:928&#x2013;947. doi: 10.1007/s13311-019-00790-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-019-00790-9</ArticleId><ArticleId IdType="pmc">PMC6985201</ArticleId><ArticleId IdType="pubmed">31686397</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P., Watt K., Kelly S.M., Clark C., Price N.C., McEwan I.J. Consequences of Poly-Glutamine Repeat Length for the Conformation and Folding of the Androgen Receptor Amino-Terminal Domain. J. Mol. Endocrinol. 2008;41:301&#x2013;314. doi: 10.1677/JME-08-0042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/JME-08-0042</ArticleId><ArticleId IdType="pubmed">18762554</ArticleId></ArticleIdList></Reference><Reference><Citation>Escobedo A., Topal B., Kunze M.B.A., Aranda J., Chiesa G., Mungianu D., Bernardo-Seisdedos G., Eftekharzadeh B., Gair&#xed; M., Pierattelli R., et al. Side Chain to Main Chain Hydrogen Bonds Stabilize a Polyglutamine Helix in a Transcription Factor. Nat. Commun. 2019;10:2034. doi: 10.1038/s41467-019-09923-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09923-2</ArticleId><ArticleId IdType="pmc">PMC6497633</ArticleId><ArticleId IdType="pubmed">31048691</ArticleId></ArticleIdList></Reference><Reference><Citation>Perutz M.F., Johnson T., Suzuki M., Finch J.T. Glutamine Repeats as Polar Zippers: Their Possible Role in Inherited Neurodegenerative Diseases. Proc. Natl. Acad. Sci. USA. 1994;91:5355. doi: 10.1073/pnas.91.12.5355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.12.5355</ArticleId><ArticleId IdType="pmc">PMC43993</ArticleId><ArticleId IdType="pubmed">8202492</ArticleId></ArticleIdList></Reference><Reference><Citation>Green H. Human Genetic Diseases Due to Codon Reiteration: Relationship to an Evolutionary Mechanism. Cell. 1993;74:955&#x2013;956. doi: 10.1016/0092-8674(93)90718-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(93)90718-6</ArticleId><ArticleId IdType="pubmed">8104707</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini G., Pigino G., Szebenyi G., You Y., Pollema S., Brady S.T. JNK Mediates Pathogenic Effects of Polyglutamine-Expanded Androgen Receptor on Fast Axonal Transport. Nat. Neurosci. 2006;9:907&#x2013;916. doi: 10.1038/nn1717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn1717</ArticleId><ArticleId IdType="pubmed">16751763</ArticleId></ArticleIdList></Reference><Reference><Citation>Rgyi Szebenyi G., Morfini G.A., Babcock A., Gould M., Selkoe K., Stenoien D.L., Young M., Faber P.W., Macdonald M.E., Mcphaul M.J., et al. Neuropathogenic Forms of Huntingtin and Androgen Receptor Inhibit Fast Axonal Transport. Neuron. 2003;40:41&#x2013;52. doi: 10.1016/S0896-6273(03)00569-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00569-5</ArticleId><ArticleId IdType="pubmed">14527432</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccioni F., Pinton P., Simeoni S., Pozzi P., Fascio U., Vismara G., Martini L., Rizzuto R., Poletti A. Androgen Receptor with Elongated Polyglutamine Tract Forms Aggregates That Alter Axonal Trafficking and Mitochondrial Distribution in Motor Neuronal Processes. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2002;16:1418&#x2013;1420. doi: 10.1096/FJ.01-1035FJE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/FJ.01-1035FJE</ArticleId><ArticleId IdType="pubmed">12205033</ArticleId></ArticleIdList></Reference><Reference><Citation>Sopher B.L., Thomas P.S., Lafevre-Bernt M.A., Holm I.E., Wilke S.A., Ware C.B., Jin L.W., Libby R.T., Ellerby L.M., La Spada A.R. Androgen Receptor YAC Transgenic Mice Recapitulate SBMA Motor Neuronopathy and Implicate VEGF164 in the Motor Neuron Degeneration. Neuron. 2004;41:687&#x2013;699. doi: 10.1016/S0896-6273(04)00082-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(04)00082-0</ArticleId><ArticleId IdType="pubmed">15003169</ArticleId></ArticleIdList></Reference><Reference><Citation>Crooke S.T., Baker B.F., Crooke R.M., Liang X. hai Antisense Technology: An Overview and Prospectus. Nat. Rev. Drug Discov. 2021;20:427&#x2013;453. doi: 10.1038/s41573-021-00162-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-021-00162-z</ArticleId><ArticleId IdType="pubmed">33762737</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamecnik P.C., Stephenson M.L. Inhibition of Rous Sarcoma Virus Replication and Cell Transformation by a Specific Oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA. 1978;75:280. doi: 10.1073/pnas.75.1.280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.75.1.280</ArticleId><ArticleId IdType="pmc">PMC411230</ArticleId><ArticleId IdType="pubmed">75545</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Lima W.F., Zhang H., Fan A., Sun H., Crooke S.T. Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs. J. Biol. Chem. 2004;279:17181&#x2013;17189. doi: 10.1074/jbc.M311683200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M311683200</ArticleId><ArticleId IdType="pubmed">14960586</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi M., Ashizawa A.T. The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery. Biomedicines. 2021;9:433. doi: 10.3390/biomedicines9040433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9040433</ArticleId><ArticleId IdType="pmc">PMC8072990</ArticleId><ArticleId IdType="pubmed">33923688</ArticleId></ArticleIdList></Reference><Reference><Citation>Havens M.A., Hastings M.L. Splice-Switching Antisense Oligonucleotides as Therapeutic Drugs. Nucleic Acids Res. 2016;44:6549. doi: 10.1093/nar/gkw533.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkw533</ArticleId><ArticleId IdType="pmc">PMC5001604</ArticleId><ArticleId IdType="pubmed">27288447</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahashi K., Katsuno M., Hung G., Adachi H., Kondo N., Nakatsuji H., Tohnai G., Iida M., Bennett F.F., Sobue G. Silencing Neuronal Mutant Androgen Receptor in a Mouse Model of Spinal and Bulbar Muscular Atrophy. Hum. Mol. Genet. 2015;24:5985&#x2013;5994. doi: 10.1093/hmg/ddv300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv300</ArticleId><ArticleId IdType="pubmed">26231218</ArticleId></ArticleIdList></Reference><Reference><Citation>Evers M.M., Pepers B.A., van Deutekom J.C.T., Mulders S.A.M., den Dunnen J.T., Aartsma-Rus A., van Ommen G.J.B., van Roon-Mom W.M.C. Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide. PLoS ONE. 2011;6:e24308. doi: 10.1371/journal.pone.0024308.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024308</ArticleId><ArticleId IdType="pmc">PMC3164722</ArticleId><ArticleId IdType="pubmed">21909428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamy F., Brondani V., Spoerri R., Rigo S., Stamm C., Klimkait T. Specific Block of Androgen Receptor Activity by Antisense Oligonucleotides. Prostate Cancer Prostatic Dis. 2003;6:27&#x2013;33. doi: 10.1038/sj.pcan.4500603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.pcan.4500603</ArticleId><ArticleId IdType="pubmed">12664061</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto Y., Loriot Y., Beraldi E., Zhang F., Wyatt A.W., Al Nakouzi N., Mo F., Zhou T., Kim Y., Monia B.P., et al. Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth. Clin. Cancer Res. 2015;21:1675&#x2013;1687. doi: 10.1158/1078-0432.CCR-14-1108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1108</ArticleId><ArticleId IdType="pubmed">25634993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Pang J., Wang Q., Yan L., Wang L., Xing Z., Wang C., Zhang J., Dong L., Wang Y., et al. Delivering Antisense Oligonucleotides across the Blood-Brain Barrier by Tumor Cell-Derived Small Apoptotic Bodies. Adv. Sci. 2021;8:2004929. doi: 10.1002/advs.202004929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202004929</ArticleId><ArticleId IdType="pmc">PMC8261483</ArticleId><ArticleId IdType="pubmed">34258157</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Kong J., Ge X., Mao M., Yu H., Wang Y. An Antisense Oligonucleotide-Loaded Blood-Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson&#x2019;s Disease. ACS Nano. 2023;17:4414&#x2013;4432. doi: 10.1021/acsnano.2c09752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.2c09752</ArticleId><ArticleId IdType="pubmed">36688425</ArticleId></ArticleIdList></Reference><Reference><Citation>Min H.S., Kim H.J., Naito M., Ogura S., Toh K., Hayashi K., Kim B.S., Fukushima S., Anraku Y., Miyata K., et al. Systemic Brain Delivery of Antisense Oligonucleotides across the Blood&#x2013;Brain Barrier with a Glucose-Coated Polymeric Nanocarrier. Angew. Chem. Int. Ed. 2020;59:8173&#x2013;8180. doi: 10.1002/anie.201914751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anie.201914751</ArticleId><ArticleId IdType="pmc">PMC7317551</ArticleId><ArticleId IdType="pubmed">31995252</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahrens-Fath I., Politz O., Geserick C., Haendler B. Androgen Receptor Function Is Modulated by the Tissue-Specific AR45 Variant. FEBS J. 2005;272:74&#x2013;84. doi: 10.1111/j.1432-1033.2004.04395.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1432-1033.2004.04395.x</ArticleId><ArticleId IdType="pubmed">15634333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson C.M., Mcphaul M.J. A and B Forms of the Androgen Receptor Are Present in human Genital Skin Fibroblasts. Proc. Natl. Acad. Sci. USA. 1994;91:1234. doi: 10.1073/pnas.91.4.1234.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.91.4.1234</ArticleId><ArticleId IdType="pmc">PMC43131</ArticleId><ArticleId IdType="pubmed">8108393</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehm S.M., Tindall D.J. Alternatively Spliced Androgen Receptor Variants. Endocr. Relat. Cancer. 2011;18:R183&#x2013;R196. doi: 10.1530/ERC-11-0141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-11-0141</ArticleId><ArticleId IdType="pmc">PMC3235645</ArticleId><ArticleId IdType="pubmed">21778211</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp A., Coleman I., Yuan W., Sprenger C., Dolling D., Rodrigues D.N., Russo J.W., Figueiredo I., Bertan C., Seed G., et al. Androgen Receptor Splice Variant-7 Expression Emerges with Castration Resistance in Prostate Cancer. J. Clin. Investig. 2018;129:192. doi: 10.1172/JCI122819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI122819</ArticleId><ArticleId IdType="pmc">PMC6307949</ArticleId><ArticleId IdType="pubmed">30334814</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonarakis E.S., Lu C., Wang H., Luber B., Nakazawa M., Roeser J.C., Chen Y., Mohammad T.A., Chen Y., Fedor H.L., et al. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer. N. Engl. J. Med. 2014;371:1028. doi: 10.1056/NEJMoa1315815.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1315815</ArticleId><ArticleId IdType="pmc">PMC4201502</ArticleId><ArticleId IdType="pubmed">25184630</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T., Karsh L.I., Nissenblatt M.J., Canfield S.E. Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer. Clin. Genitourin. Cancer. 2020;18:1&#x2013;10. doi: 10.1016/j.clgc.2019.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clgc.2019.09.015</ArticleId><ArticleId IdType="pubmed">31653572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim W.F., Forouhan M., Roberts T.C., Dabney J., Ellerington R., Speciale A.A., Manzano R., Lieto M., Sangha G., Banerjee S., et al. Gene Therapy with AR Isoform 2 Rescues Spinal and Bulbar Muscular Atrophy Phenotype by Modulating AR Transcriptional Activity. Sci. Adv. 2021;7:eabi6896. doi: 10.1126/sciadv.abi6896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abi6896</ArticleId><ArticleId IdType="pmc">PMC8378820</ArticleId><ArticleId IdType="pubmed">34417184</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidersbach A.J., Dorighi K.M., Gomez J.A., Jacobi A.M., Haley B. A Versatile, High-Efficiency Platform for CRISPR-Based Gene Activation. Nat. Commun. 2023;14:1&#x2013;10. doi: 10.1038/s41467-023-36452-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36452-w</ArticleId><ArticleId IdType="pmc">PMC9938141</ArticleId><ArticleId IdType="pubmed">36804928</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Maria V., Moindrot M., Ryde M., Bono A., Quintino L., Ledri M. Development and Validation of CRISPR Activator Systems for Overexpression of CB1 Receptors in Neurons. Front. Mol. Neurosci. 2020;13:526700. doi: 10.3389/fnmol.2020.00168.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2020.00168</ArticleId><ArticleId IdType="pmc">PMC7506083</ArticleId><ArticleId IdType="pubmed">33013319</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok A., Raulf N., Habib N. Developing Small Activating RNA as a Therapeutic: Current Challenges and Promises. Ther. Deliv. 2019;10:151&#x2013;164. doi: 10.4155/tde-2018-0061.</Citation><ArticleIdList><ArticleId IdType="doi">10.4155/tde-2018-0061</ArticleId><ArticleId IdType="pubmed">30909853</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanbarian H., Aghamiri S., Eftekhary M., Wagner N., Wagner K.D. Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments. Cells. 2021;10:591. doi: 10.3390/cells10030591.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10030591</ArticleId><ArticleId IdType="pmc">PMC8001863</ArticleId><ArticleId IdType="pubmed">33800164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim K.R.Q., Woo S., Melo D., Huang Y., Dzierlega K., Shah M.N.A., Aslesh T., Roshmi R.R., Echigoya Y., Maruyama R., et al. Development of DG9 Peptide-Conjugated Single- and Multi-Exon Skipping Therapies for the Treatment of Duchenne Muscular Dystrophy. Proc. Natl. Acad. Sci. USA. 2022;119:e2112546119. doi: 10.1073/pnas.2112546119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2112546119</ArticleId><ArticleId IdType="pmc">PMC8892351</ArticleId><ArticleId IdType="pubmed">35193974</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton H.M., Moulton J.D. Morpholinos and Their Peptide Conjugates: Therapeutic Promise and Challenge for Duchenne Muscular Dystrophy. Biochim. Biophys. Acta (BBA)-Biomembr. 2010;1798:2296&#x2013;2303. doi: 10.1016/j.bbamem.2010.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2010.02.012</ArticleId><ArticleId IdType="pubmed">20170628</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>